Novartis in the lead to acquire cancer drug developer MorphoSys

6 February 2024, 12:00 am

1 min read

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the company's French headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau/File Photo

Reuters exclusively reported that drug maker Novartis AG (NOVN.S) is in advanced talks to acquire MorphoSys AG (MORG.DE), a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion).